ArticleCrohn's & colitis 3602025
Real-World Effectiveness of Risankizumab in Crohn's Disease: Outcome Data for an IL-23 Inhibitor from the Middle East.
Article in Crohn's & colitis 360, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.Alimentary pharmacology & therapeutics · 2026Observational
- Interleukin-23 Inhibitors in Inflammatory Bowel Disease.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Real-world effectiveness of guselkumab for induction of remission in Crohn's disease: a prospective multicenter cohort study with propensity score-matched comparison to risankizumab.Crohn's & colitis 360 · 2026Article
- Acceptability and tolerability of risankizumab maintenance therapy administered via on-body injector in patients with Crohn's disease: Results of the ACCEPT-OBI study.Therapeutic advances in gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Crohn's disease (CD) in the Middle East is often aggressive, yet regional patients are underrepresented in pivotal trials for new therapies. This study is the first real-world evaluation of risankizumab's effectiveness, safety, and dose optimization in a predominantly Emirati cohort with moderate-to-severe CD. Methods: This prospective cohort included 60 UAE patients with moderate-to-severe CD initiating risankizumab. Endpoints included clinical remission (CDAI <150) and biochemical remission (normalised C-reactive protein <5 mg/L and faecal calprotectin <250 µg/g), assessed post-induction (weeks 12-20) and at maintenance (10-14 months). Logistic regression models were used to identify predictors of remission and the need for dose intensification. Results: The median age was 33 years, and 61.7% were advanced therapy (AT)-exposed. Post-induction, clinical remission was achieved in 46.7% of patients, with significantly higher rates in AT-naïve vs AT-exposed patients (69.6% vs 32.4%, Conclusion: This first Middle Eastern real-world study confirms risankizumab is effective and safe for complex CD and supports its use across different treatment lines.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.